Lehi Vidigal

Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer

Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the company ST. LOUIS, MO, and SAN DIEGO, CA, April 14, 2021 – Wugen Inc., a clinical stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies, today announced the …

Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer Read More »

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement with Shanghai-based Alpha Biopharma Inc. to manufacture, develop, and commercialize its allogeneic cell products …

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer Read More »

Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer

ST. LOUIS, MO, March 2, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license agreement with US-based HCW Biologics Inc. (HCW) for the use of their proprietary fusion molecules to manufacture Wugen’s cellular therapeutics for the treatment of cancer. …

Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer Read More »

Wugen Announces the Appointment of Company’s Co-founder, Matt Cooper, Ph.D., as Chief Scientific Officer

ST. LOUIS, March 1, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of the company’s co-founder, Matt Cooper, Ph.D., as the Chief Scientific Officer (CSO). Dr. Cooper will be supervising the research and development of a universal truly “off-the-shelf” and fratricide-resistant CAR-T cell therapy for …

Wugen Announces the Appointment of Company’s Co-founder, Matt Cooper, Ph.D., as Chief Scientific Officer Read More »

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis, one of the world’s leading research institutions, for the development of Wugen’s Memory Natural Killer (NK) Cell program.   While …

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis Read More »

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s Chief Medical Officer (CMO).  A leader in oncology research and development, Dr. Davidson has a firsthand understanding of successful design and implementation of oncology clinical …

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs Read More »

Scroll to Top